Madrigal's 15min Chart Indicates Bearish Signals with MACD & KDJ Death Crosses

Madrigal's 15-minute chart has recently triggered a MACD Death Cross and a KDJ Death Cross, which occurred on August 28, 2025 at 14:15. This development suggests that the stock price may experience a continuation of its downward trend, with momentum shifting towards the downside and potentially leading to further decreases in value.

Madrigal Pharmaceuticals Inc. (MDGL) has recently experienced a significant technical setback, with its 15-minute chart triggering both a MACD Death Cross and a KDJ Death Cross on August 28, 2025, at 14:15. This development suggests a potential continuation of the stock's downward trend, indicating a shift in momentum towards the downside and a possible further decline in value [1].

Madrigal Pharmaceuticals has been in the spotlight for its innovative approach to treating liver fibrosis. In March 2024, the company's drug Rezdiffra (resmetirom) became the first FDA-approved treatment for MASH (metabolic dysfunction-associated steatohepatitis), a condition characterized by liver scarring due to fatty liver disease. The company anticipates strong revenue growth for Rezdiffra, with potential annual sales reaching nearly $5 billion by 2031 [1].

Despite this promising pipeline, the recent technical indicators signal a challenging period for the stock. The MACD Death Cross and KDJ Death Cross are both indicators that suggest a change in the stock's trend, often signaling a potential reversal. This development could be a cause for concern for investors, as it suggests a possible continuation of the stock's downward trend.

Madrigal Pharmaceuticals is not without its challenges. The company's stock price has been volatile, and the recent technical setbacks could be a reflection of broader market sentiment or specific concerns about the company's pipeline. However, it is important to note that technical indicators are not the only factor to consider when making investment decisions. Fundamental analysis, which focuses on the company's financial health and business prospects, is also crucial.

Investors should closely monitor the situation and consider the broader context when evaluating Madrigal Pharmaceuticals' stock. The company's pipeline of innovative treatments for liver fibrosis is promising, and the recent FDA approvals for Rezdiffra are a testament to the company's progress. However, the recent technical setbacks suggest that the stock may face further challenges in the short term.

References:
[1] https://www.benzinga.com/analyst-stock-ratings/initiation/25/08/47342596/gyre-therapeutics-gains-attention-as-under-the-radar-liver-fibrosis-drug-maker